Grail Analyst Sees Massive Market Potential with Valuation Headwinds
RBC initiated coverage of Grail with a Sector Perform rating and $84 target, citing Galleri’s potential and upcoming FDA panel.
Share
Why It Matters
RBC thinks Grail's blood test could be really useful someday. But they say the stock price might be too high right now.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.